Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) (OTCPK:ESAIY) announced that the U.S. Food and Drug Administration (FDA) ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Bristol Myers Squibb CEO Chris Boerner described Cobenefy, a new drug to treat schizophrenia and may also help with bipolar ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Biologics ...

Potential New Therapeutic Targets for Huntington's Disease Jan. 8 ... Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative ...

Discover how dopamine’s unexpected role in breaking down harmful plaques could revolutionize Alzheimer's treatment and ...

There’s intriguing news today about a technology that could improve treatment in people with Alzheimer’s. It uses sound waves ...

A University of the Basque Country (UPV/EHU) study proves that the WIN55.212-2 drug protects the brain and reverses the ...

Both drugs work by reducing the brain amyloid levels in patients in the early stages of Alzheimer’s, and act to slow the disease. Still, they don’t stop or reverse it, while both treatments have side ...